Effects of albendazole treatment on neurocysticercosis: A randomised controlled trial

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 79, Issue 9, 2008, Pages 1050-1055

  Carpio, A ^a,b   Kelvin, E A ^b,c   Bagiella, E ^d   Leslie, D ^e,f   Leon, P ^g   Andrews, H ^c,d   Hauser, W A ^b,d   Lisanti, Noemi ^h   Aguirre, Rafael ⁱ   Serrano, Marcos ^j   Pesantes, Jorge ^k   Moncayo, Jorge ^k   Roman, Marcelo ^l  

^a UNIVERSIDAD DE CUENCA   (Ecuador)

^b Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^d Good Samaritan Hospital ^*  (United States)

^e MRI Diagnostics of Westchester   (United States)

^f Good Samaritan Hospital Suffern   (United States)

^g Instituto de Diagnóstico Por Imágenes   (Ecuador)

^h Carlos Andrade Marín Hospital ^*  (United States)

ⁱ Hospital Regional Teodoro Maldonado Carbo   (Ecuador)

^j HOSPITAL CARLOS ANDRADE MARÍN   (Ecuador)

^k HOSPITAL EUGENIO ESPEJO   (Ecuador)

^l Baca Ortiz Hospital   (Ecuador)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBENDAZOLE; CARBAMAZEPINE; PREDNISONE;

ADULT; ARTICLE; CALCIFICATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; NEUROCYSTICERCOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEIZURE; TREATMENT RESPONSE;

EID: 50449094016     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2008.144899     Document Type: Article

References (31)

1. White A. Neurocysticercosis. Curr Treat Options Infect Dis 2000;2:78-87.
2. Carpio A, Hauser W. Prognosis for seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 2002;59:1730-4.
3. Hawk M, Shahlaie K, Kim K, et al. Neurocysticercosis in the United States: review of an important emerging infection. Neurology 2004;63:1559-64.
4. Schantz P. Taenia solium cysticercosis: an overview of global distribution and transmission. Oxon, UK: CABI Publishing, 2002:63-74.
5. Garcia H, Pretell E, Gilman R, et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 2004;350:249-58.
6. Singh G, Sander J. Anticysticercal treatment and seizures in neurocysticercosis. Lancet Neurol 2004;3:207-8.
7. Takayanagui O. Therapy for neurocisticercosis. Expert Rev Neurother 2004;4:129-39.
8. Caplan L, Estanol B, Mitchel W, et al. How to manage patients with neurocysticercosis. Eur Neurol 2997;37:124-31.
9. Salinas R, Prasad K. Drugs for treating neurocysticercosis (tapeworm infection of the brain). Oxford: Update Software, 2005.
10. Carpio A, Escobar A, Hauser W. Cysticercosis and epilepsy: a critical review. Epilepsia 1998;39:1025-40.
11. Del Brutto O, Roos K, Coffey C, et al. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 2006;145:43-51.
12. Evans C, Garcia H, Gilman R, et al. Controversies in the management of cysticercosis. Emerg Infect Dis 1997;3:403-5.
13. Carpio A, Placencia M, Santillán F, et al. A proposal for a classification of neurocysticercosis. Can J Neuro Sci 1994;21:43-7.
14. Garcia HH, Gilman RH, Horton J, et al. Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Neurology 1997;48:1421-7.
15. GlaxoSmithKline. ALBENZA. Available at: http://us.gsk.com/ products/assets/us_albenza.pdf (accessed 24 June 2008).
16. Fleiss J. Statistical methods for rates and proportions. New York: John Wiley & Sons, 1981:218.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. JASA 1958;53:457-81.
18. Kelley R, Duong D, Locke G. Characteristics of ventricular shunt malfunctions among patients with neurocysticercosis. Neurosurgery 2002;50:757-62.
19. Colli B, Pereira C, Assirati JJ, et al. Isolated fourth ventricle in neurocysticercosis: pathophysiology, diagnosis, and treatment. Surg Neurol 1993;39:305-10.
20. McCormick G. Cysticercosis - review of 230 patients. Bull Clin Neurosci 1985;50:76-101.
21. Singhi P, Jain V, Khandelwal N. Corticosteroids versus albendazole for treatment of single small enhancing computed tomographic lesions in children with neurocysticercosis. J Child Neurol 2004;19:323-7.
22. Padma M, Behari M, Misra N, et al. Albendazole in single CT ring lesions in epilepsy. Neurology 1994;44:1344-6.
23. Rajshekhar V. Rate of spontaneous resolution of a solitary cysticercus granuloma in patients with seizures. Neurology 2001;57:2315-17.
24. Gogia S, Talukdar B, Choudhury V, et al. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 2003;97:416-21.
25. Garcia H, Evans C, Nash T, et al. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15:747-56.
26. Carpio A, Santillén F, León P, et al. Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Int Med 1995;155:1982-8.
27. Rajshekhar V, Lakshmanan J. Seizure outcome in patients with a solitary cerebral cysticercus granulomas. Neurology 2004;62:2236- 40.
28. Baranwal AK, Singhi PD, Khandelwal N, et al. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled, double blind trial. Pediatr Infect Dis J 1998;17:696-700.
29. Gogia S, Talukdar B, Choudhury V, et al. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 2003;97:416-21.
30. Kalra V, Dua T, Kumar V. Efficacy of albendazole and short-course dexamethasone treatment in children with 1 or 2 ring-enhancing lesions of neurocysticercosis: a randomized controlled trial. J Pediatr 2003;143:111-14.
31. Nash T, Singh G, White A, et al. Treatment of neurocysticercosis: current status and future research needs. Neurology 2006;67:1120-7.